Staphylococcus epidermidis

Staphylococcus epidermidis is a Gram-positive bacterium that is a ubiquitous member of the human microbiota, predominantly colonizing the skin. Long regarded as a harmless commensal, it is now recognized as a leading cause of nosocomial infections, particularly those associated with indwelling medical devices. Its ability to form resilient biofilms on artificial surfaces is central to its pathogenesis and presents a major challenge in modern healthcare.

Characteristics and identification

This bacterium appears as grape-like clusters of cocci when viewed under a microscope and tests positive in the catalase test but negative in the coagulase test, a key feature distinguishing it from the more virulent Staphylococcus aureus. It is a facultative anaerobe capable of growth in both aerobic and anaerobic conditions. Colonies on blood agar are typically non-hemolytic, small, and white. Identification in the clinical microbiology laboratory often involves automated systems like VITEK or MALDI-TOF, which analyze biochemical profiles or protein spectra, respectively. Its natural habitat is the human skin, where it is one of the most abundant bacterial species, playing a role in microbial ecology by outcompeting potential pathogens.

Pathogenesis and virulence factors

The primary virulence determinant is its extraordinary capacity to adhere to surfaces and form a biofilm, a structured community of bacteria encased in a self-produced extracellular polymeric substance. Initial attachment is mediated by surface proteins like autolysin AtlE and accumulation-associated protein. The biofilm matrix, composed of polysaccharide intercellular adhesin synthesized by the icaADBC operon, provides protection against host immune system defenses such as phagocytosis and complement system attack, as well as a barrier against antimicrobial agents. Other factors include phenol-soluble modulins, which exhibit pro-inflammatory activity and can lyse red blood cells, and the ability to acquire iron from host proteins like transferrin.

Clinical significance and infections

As a leading agent of device-associated infections, it is a major cause of bloodstream infections related to central venous catheters, infective endocarditis on prosthetic heart valves, and infections of orthopedic implants, pacemakers, and cerebrospinal fluid shunts. It is also a common contaminant in blood cultures, complicating diagnosis. In neonatal intensive care unit settings, it can cause serious sepsis in preterm infants. Outside of healthcare, it rarely causes disease in immunocompetent individuals but can be involved in wound infections or urinary tract infections, particularly in those with compromised defenses.

Antibiotic resistance

It exhibits remarkably high levels of antimicrobial resistance, with the vast majority of clinical isolates now resistant to methicillin, classified as methicillin-resistant Staphylococcus epidermidis. This resistance is conferred by the mecA gene, which codes for an altered penicillin-binding protein PBP2a with low affinity for beta-lactam antibiotics. Many strains are also resistant to other drug classes, including aminoglycosides, macrolides, and fluoroquinolones, often harboring these resistance genes on plasmids or within the staphylococcal cassette chromosome mec. The biofilm mode of growth further drastically reduces susceptibility to antibiotics, making infections notoriously difficult to eradicate.

Prevention and treatment

Prevention focuses on strict aseptic technique during the insertion and maintenance of catheters and implants, and the use of antimicrobial- or silver-coated devices. Treatment of confirmed infections typically requires removal of the infected device, as antibiotics alone are often ineffective against established biofilms. For systemic treatment, the glycopeptide antibiotic vancomycin remains a cornerstone, though vancomycin-resistant strains are emerging. Alternative agents include daptomycin, linezolid, and tedizolid, especially for infections caused by strains resistant to multiple drugs. Research into novel strategies, such as quorum sensing inhibitors and bacteriophage therapy, is ongoing.

Category:Bacillota Category:Staphylococcaceae